Biofrontera Revenue Jumps 15% in Q2
(NASDAQ:BFRI), a specialty biopharmaceutical company focused on dermatology solutions, released its financial results for the second quarter of fiscal 2025 on August 13, 2025. The headline news was a jump in revenue—totaling $9.0 million (GAAP)—which outpaced analyst expectations of $8.3 million, resulting in an 8.4% beat. Sales were driven by higher demand and improved pricing for Ameluz®, its main product. Despite the revenue growth and evidence of commercial progress, the bottom line moved in the opposite direction. Biofrontera posted a net loss per share of $(0.57) (GAAP), missing the consensus estimate of $(0.42). The wider loss was largely the result of a significant increase in legal expenses. Overall, the quarter showed top-line momentum but highlighted ongoing challenges with profitability and cost control.
Source: Analyst estimates for the quarter provided by FactSet.
Biofrontera develops and markets dermatological drugs and medical devices to treat skin conditions, with a main focus on actinic keratosis—a type of pre-cancerous skin lesion. Its principal product, Ameluz®, is a prescription medicine used with the company’s RhodoLED® photodynamic therapy (PDT) lamps for skin treatments.
Source Fool.com
